Overview

CJC-1295, a synthetic growth hormone-releasing hormone (GHRH) analog, was developed to enhance plasma growth hormone (GH) levels. Its development is attributed to the work of researchers at ConjuChem, a biotechnology company, who aimed to create a longer-lasting alternative to naturally occurring GHRH. The objective was to produce a compound that could sustain elevated levels of GH, a hormone critical for growth, metabolism, and tissue repair.

CJC-1295 functions by mimicking the action of GHRH, the hormone responsible for signaling the pituitary gland to release GH. Its unique structure allows it to bind effectively to the GHRH receptor, leading to a more sustained release of GH compared to natural GHRH. This prolonged action results from its ability to avoid rapid degradation and clearance from the body, extending its duration of action significantly.

Clinical trials of CJC-1295 have primarily focused on its potential to increase GH levels and its effects on muscle growth and fat loss. These studies have generally demonstrated that CJC-1295 can effectively increase GH and IGF-1 levels, which are crucial mediators of growth hormone's effects in the body. However, the clinical trials have not been extensive enough to fully establish its efficacy and safety profile for long-term use. CJC-1295 is often mixed with Drug Affinity Complex (or “DAC”) to increase it’s half-life from under ten minutes to up to eight days.

In the context of athletics and performance enhancement, CJC-1295 has garnered attention due to its potential to promote muscle growth and improve recovery. Athletes and bodybuilders are interested in its ability to stimulate GH release, which is associated with increased muscle mass and reduced body fat. However, it's important to note that the use of CJC-1295 for athletic performance enhancement is not supported by clinical research and falls outside the bounds of legal and ethical sports practices. Its use in professional sports is banned by many anti-doping agencies.

While CJC-1295 represents an intriguing area of research in hormone therapy and sports medicine, its use requires careful consideration due to the lack of comprehensive safety data and its status within sports regulations.

Dosage

When calculating the dosage for CJC-1295 DAC (Drug Affinity Complex), it's important to consider that this particular form of CJC-1295 has an extended half-life, typically requiring less frequent dosing than the non-DAC version. The common dosing strategy for CJC-1295 DAC varies, but a general guideline can be provided.

Please note: The following calculations are for informational purposes only. Actual dosing should always be determined and supervised by a healthcare professional.

1. Concentration Calculation:

   • A 2 mg (or 2000 mcg, since 1 mg = 1000 mcg) vial of CJC-1295 DAC is mixed with 2 mL of bacteriostatic water.

   • This results in a concentration of 2000 mcg / 2 mL = 1000 mcg/mL.

2. Typical Dosage:

   • CJC-1295 DAC is often dosed at 1000 mcg to 2000 mcg per week, usually split into one or two doses.

   • Let's calculate for a common weekly dose of 1000 mcg, which could be administered as a single weekly injection.

3. Volume Calculation for 1000 mcg:

   • Volume in mL for a 1000 mcg dose: 1000 mcg1000 mcg/mL=1.0 mL1000 mcg/mL1000 mcg​=1.0 mL.

4. Syringe Measurement:

   • In a 0.5 mL, 50-unit insulin syringe, each unit is equivalent to 0.01 mL (since 0.5 mL = 50 units).

   • For a 1.0 mL dose: 1.0 mL×100 units/mL=100 units1.0 mL×100 units/mL=100 units.

Therefore, to administer a dose of 1000 mcg of CJC-1295 DAC from your prepared solution, you would need to draw up to the 100-unit mark on a 0.5 mL, 50-unit insulin syringe. Given the size of the dose and the syringe capacity, it might require two injections to administer the full dose if using 0.5 mL syringes.

Remember, the specific dosage and frequency should be tailored to individual needs and overseen by a healthcare professional.